Steve Duff1, Rodrigo Hasbun2, Christine C Ginocchio3,4,5, Joan-Miquel Balada-Llasat6, Louise Zimmer3, Samuel A Bozzette3,7. 1. Veritas Health Economics Consulting, Carlsbad, CA, USA. 2. UTHealth McGovern Medical School, Houston, TX, USA. 3. bioMérieux, Durham, NC, USA. 4. BioFire Diagnostics, Salt Lake City, UT, USA. 5. Department of Pathology and Laboratory Medicine, Hofstra Northwell School of Medicine, Hempstead, NY, USA. 6. The Ohio State University Wexner Medical Center, Columbus, OH, USA. 7. University of California, San Diego, CA, USA.
Abstract
AIM: We assessed the possible economic impact of a rapid test in pediatric patients with suspected community-acquired meningitis/encephalitis. MATERIALS & METHODS: Modeling simulated diagnosis, clinical decisions, resource use/costs of standard of care (SOC) and two cerebrospinal fluid testing strategies using FilmArray® (FA), a US FDA-cleared system that provides results in approximately 1 h. RESULTS: Pathogens detected by FA caused approximately 75% of cases, 97% of which would be accurately diagnosed with FA. Mean cost/case ranged from $17,599 to $22,025. Syndromic testing is less expensive than SOC. Testing all suspected cases yielded greater savings ($3481/case) than testing only those with abnormal cerebrospinal fluid ($2157/case). CONCLUSION: Greater economic benefits are achievable with syndromic testing of all cases, rather than SOC or targeted syndromic testing.
AIM: We assessed the possible economic impact of a rapid test in pediatric patients with suspected community-acquired meningitis/encephalitis. MATERIALS & METHODS: Modeling simulated diagnosis, clinical decisions, resource use/costs of standard of care (SOC) and two cerebrospinal fluid testing strategies using FilmArray® (FA), a US FDA-cleared system that provides results in approximately 1 h. RESULTS: Pathogens detected by FA caused approximately 75% of cases, 97% of which would be accurately diagnosed with FA. Mean cost/case ranged from $17,599 to $22,025. Syndromic testing is less expensive than SOC. Testing all suspected cases yielded greater savings ($3481/case) than testing only those with abnormal cerebrospinal fluid ($2157/case). CONCLUSION: Greater economic benefits are achievable with syndromic testing of all cases, rather than SOC or targeted syndromic testing.